Member Info for PM2022

I was the only person here that stated board changes the way it was happening was wrong not because I felt the previous board did a brilliant job but that it was going to cause issues in regards to timings, ongoing negotiations and you cannot replace years of experience with a bunch newbies regardless of skills they may have. Some change was needed but the way it was done led to a complete clear out and now Martin finds himself building contacts and trying to establish what to do. They are probably just depending on the broker on many aspects whereas the old board would likely have found enough time to time things and the experience.

People were thrown out of Telegram if they never did exactly what was asked of them but they never wanted to discuss anything with anyone so I expect them to find a solution for shareholders.

Valirx has potential and should never be at the current price. At the moment lots of scenarios are in play so anything is possible with the deadlines we have.

The website looks updated. Under the current pipeline Val401 remains. I'm expecting news soon.

New website coming soon. Please bear with us while we redevelop our site.

The deal for 201 will release funds from investors. If floated on the stock exchange and valued at 100-500 million for the entire pipeline in the US Valirx gets 201 cash plus have the option to sell the 0.5% stake which could bring an extra million or two depending on valuations.

Milestones and deals help support a placing without any real discount as it attracts buyers even in the open market so although upfront cash matters it is not only about that.

The blind leading the blind.

They only need 201 or 401 with just over a month left for the deadline. Might be tight but in the balance here.

Yes, I'll be having the last laugh before 31 December 2024. Looking forward to it.

Valirx will get the chance. In the US it could be worth 200/300/400 million on launch??

2 clinical drugs plus 2 pre clinical. Valirx can then sell into the launch and claim a few millions????

Only needs one. 201 looks very likely imo. You don't meet twice a week and put credibility on the line and bother with an extra 0.5% equity. The deal will likely now be very, very valuable at this market cap.

To prove you are wrong remember it requires considerable legal work to change the terms. Nobody wastes time doing that without evidence of progress.

It is based on progress after 3 years. 2 significant deals that will impact the market cap at this price.

Market makers opened us up at 65p last time If a deal is announced with the 0.5% which could be proven to be very valuable it will likely prove to be a problem to get back in. Difficult decisions.

THX has 4 drugs if I remember correctly with 2 being clinical. The 0.5% alone will likely be worth a million or more imo.

Credibility on the line. Given they have been raising for 3 years so it is fair to assume that all is good and they likely have the cash.

The deal can complete in the next few weeks and it could also be a limited placing with hardly any discount given our current market cap.

2 deals by year end.

They would have raised the money in that case. Must be doing all the legal stuff.

One potential outcome that others have not considered is that if 201 is not concluded they could release an update and remove the uncertainty with some facts and a final deadline. Also announcing a tiny placing so if the deadline was for 2/3 months placing to cover 4 months with warrants which gives even more cash. It would not require much digging in to get that filled once 201 completes then they can then attract larger II investment. 401 comes into that equation if due to complete within that time as expected.

Just saying different ways to work around this but it comes down to decision making.

But bearing in mind this can quickly move to 4/5p or more with the right news.

Sorry but I see no logic in issuing so much extra shares. It would not be attractive to have so much overhang for new holders. Hardly a discount if you flood the market by an equal proportion of extra shares . I would say 15-20% and that is just an honest opinion rather than constant childish deramping attempting to scare people.

We are heading at least to some conclusion in regards to Val201 and Val 401 so I would think given our SP we might get some decent news first in the next week or two that would make a larger discount even more unlikely.

Glad Friday is out of the way.

Getting close to Val 401 deadline date.

Expecting news on Val201 first hopefully with decent cash.

Stingray evaluation project due early November.

If both deals happen expecting double digits price even with positive 201 news will be difficult to get in at these prices.

VAL201: This compound is targeting hormone-resistant prostate cancer, a significant area of unmet need. In preclinical and early-stage trials, VAL201 has shown efficacy in blocking tumor growth. ValiRx signed a service agreement with TheoremRx to develop this asset, which could lead to substantial future returns if clinical milestones are achieved​

VALIRX

VAL301: A non-oncology variant of VAL201, this compound is being developed for treating endometriosis, expanding ValiRx's market potential across women's health​

2. Partnerships and Industry Validation

ValiRx's partnerships with other companies and organizations show external validation of its science:

TheoremRx Partnership: The deal with TheoremRx for VAL201 demonstrates that ValiRx has attracted industry interest.

.

Cancer Research Technology (CRT): The licensing deal with CRT to develop prostate cancer treatments highlights that VAL201 is based on a compound with a solid scientific foundation.

At the end of the day, everyone needs to make their own investment decisions. If my perspective has been convincing to some, that's just part of the discussion. But I understand your frustration.

Cash.